Article

OPKO Health acquires company developing glaucoma shunt

Miami-OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.

Miami-

OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.

The patented device was designed by M. Bruce Shields, MD, chairman emeritus, Department of Ophthalmology and Visual Science, Yale University School of Medicine. He is chief scientific and medical officer at Vidus Ocular.

“Preclinical data on the device are encouraging, and we believe that OPKO is an ideal partner to assume responsibility for the development and commercialization of this potentially important product,” he said.

Naveed Shams, MD, PhD, OPKO chief medical officer and senior vice president of research and development, said that the device “has the potential for a relatively rapid and straightforward development and regulatory pathway. We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business.”

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
© 2024 MJH Life Sciences

All rights reserved.